Listed
Stock Code: 005690
| Company Name | 파미셀(주) |
| English Name | Pharmicell Co.,Ltd. |
| Business Reg. No. | 3148100664 |
| CEO | 김현수 |
| Address | 서울특별시 강남구 언주로 874 (신사동, 쌍봉빌딩 7층) |
| Industry | 그 외 기타 분류 안된 화학제품 제조업 |
| Industry Code | 211 |
| Main Products | 줄기세포치료제 |
| Established | 1968-08-20 |
| Phone | 02-3496-0114 |
| Website | www.pharmicell.com |
| Regular Employees | 16persons |
| Corp. Reg. No. | 1601110005177 |
Venture Certified
| 신기술기업(고도기술수반산업) | 2004-10-21 ~ 2006-10-20 | 041635032100790 | - |
| 연구개발유형 | 2007-10-21 ~ 2008-10-20 | 20060100269 | - |
| 연구개발유형 | 2008-10-21 ~ 2010-10-20 | 20080106373 | - |
| 연구개발유형 | 2010-10-21 ~ 2012-10-20 | 20100107415 | - |
| 연구개발유형 | 2012-11-26 ~ 2014-11-25 | 20120109156 | 2012-11-26 |
| 연구개발유형 | 2014-11-26 ~ 2016-11-25 | 20140113142 | 2012-11-26 |
| 연구개발유형 | 2016-11-26 ~ 2018-11-25 | 20160113148 | 2012-11-26 |
| 연구개발유형 | 2018-11-26 ~ 2020-11-25 | 20180113619 | 2012-11-26 |
| 연구개발유형 | 2020-11-26 ~ 2022-11-25 | 20200116583 | 2012-11-26 |
| 연구개발유형 | 2022-11-26 ~ 2025-11-25 | 20221222020003 | 2012-11-26 |
| 연구개발유형 | 2025-11-26 ~ 2028-11-25 | 20251216020010 | 2012-11-26 |
Revenue CAGR +3.8%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 649B | 562B | 602B |
| Operating Profit | 47B | 13B | 89B |
| Net Profit | 63B | 47B | 60B |
| Total Assets | 993B | 925B | 1,096B |
| Total Liabilities | 128B | 121B | 330B |
| Total Equity | 864B | 804B | 767B |
▲ 11.4%
▼ 8.4%
▼ 15.8%
▼ 48.9%
▲ 6.0%
| Name | Position | Role |
|---|---|---|
| 김현수 | 대표이사 | 대표 |
| NPS Subscribers | 16persons |
| CEO | 김현수 |
| Est. Avg. Annual Salary | 5,19310K (43310K/mo) |
| Hired (12 mo) | +2persons |
| Left (12 mo) | -1persons |
| Net Change (12 mo) | +1persons |
| NPS Join Date | 1993-06-25 |
| Patent Title | Applicant | Application No. | Filing Date | Status |
|---|---|---|---|---|
| 배양용기, 이를 포함하는 세포배양장치 및 세포배양방법 | 파미셀 주식회사 | 1020230131211 | 2023-09-27 | 공개 |
| 배양용기, 이를 포함하는 세포배양장치 및 세포배양방법 | 파미셀 주식회사 | 1020230131201 | 2023-09-27 | 공개 |
| 졸레드로네이트를 통해 성숙된 WT1 정보를 가진 인간 CD141+ 수지상세포 | 파미셀 주식회사 | 1020230106758 | 2023-08-16 | 공개 |
| 뉴클레오시드 함유 세포 배양배지 및 이를 이용한 세포 배양 방법 | 파미셀 주식회사 | 1020230093184 | 2023-07-18 | 공개 |
| 대용량 고순도의 2'-디옥시-2'-플루오로우리딘의 제조 방법 | 파미셀 주식회사 | 1020230049169 | 2023-04-14 | 등록 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
2 Additional Data Sources
{
"address": "서울특별시 강남구 언주로",
"brno": "314810****",
"cappedWarning": false,
"companyName": "파미셀(주)",
"estimatedAvgAnnualSalary": 51930468,
"estimatedAvgMonthlySalary": 4327539,
"fetchedAt": "2026-03-05T11:07:05.859Z",
"industryCode": "171109",
"industryName": "화학섬유직물 직조업",
"joinDate": "19930625",
"last12MonthsHired": 2,
"last12MonthsLeft": 1,
"last12MonthsNetChange": 1,
"leaveDate": null,
"monthlyPensionAmount": 6577860,
"monthlyTrend": [
{
"lostSubscribers": 1,
"newSubscribers": 2,
"yearMonth": null
}
],
"npsRateUsed": 0.095,
"npsUpperCap": 6370000,
"seq": "6389670",
"status": "1",
"styleCode": "1",
"subscriberCount": 16,
"turnoverMonths": 1
}{
"address": "서울특별시 강남구",
"ceo_name": "김현수",
"certificate": [
{
"cert_number": "041635032100790",
"changes": "",
"disclosure_date": "2004-10-21",
"first_cert_date": "",
"no": "1",
"type": "신기술기업(고도기술수반산업)",
"valid_period": "2004-10-21 ~ 2006-10-20"
},
{
"cert_number": "20060100269",
"changes": "",
"disclosure_date": "2006-10-18",
"first_cert_date": "",
"no": "2",
"type": "연구개발유형",
"valid_period": "2007-10-21 ~ 2008-10-20"
},
{
"cert_number": "20080106373",
"changes": "",
"disclosure_date": "2008-09-26",
"first_cert_date": "",
"no": "3",
"type": "연구개발유형",
"valid_period": "2008-10-21 ~ 2010-10-20"
},
{
"cert_number": "20100107415",
"changes": "",
"disclosure_date": "2010-11-02",
"first_cert_date": "",
"no": "4",
"type": "연구개발유형",
"valid_period": "2010-10-21 ~ 2012-10-20"
},
{
"cert_number": "20120109156",
"changes": "",
"disclosure_date": "2012-11-26",
"first_cert_date": "2012-11-26",
"no": "5",
"type": "연구개발유형",
"valid_period": "2012-11-26 ~ 2014-11-25"
},
{
"cert_number": "20140113142",
"changes": "",
"disclosure_date": "2014-12-15",
"first_cert_date": "2012-11-26",
"no": "6",
"type": "연구개발유형",
"valid_period": "2014-11-26 ~ 2016-11-25"
},
{
"cert_number": "20160113148",
"changes": "",
"disclosure_date": "2016-11-23",
"first_cert_date": "2012-11-26",
"no": "7",
"type": "연구개발유형",
"valid_period": "2016-11-26 ~ 2018-11-25"
},
{
"cert_number": "20180113619",
"changes": "",
"disclosure_date": "2018-11-30",
"first_cert_date": "2012-11-26",
"no": "8",
"type": "연구개발유형",
"valid_period": "2018-11-26 ~ 2020-11-25"
},
{
"cert_number": "20200116583",
"changes": "",
"disclosure_date": "2020-12-24",
"first_cert_date": "2012-11-26",
"no": "9",
"type": "연구개발유형",
"valid_period": "2020-11-26 ~ 2022-11-25"
},
{
"cert_number": "20221222020003",
"changes": "",
"disclosure_date": "2022-12-22",
"first_cert_date": "2012-11-26",
"no": "10",
"type": "연구개발유형",
"valid_period": "2022-11-26 ~ 2025-11-25"
},
{
"cert_number": "20251216020010",
"changes": "",
"disclosure_date": "2025-12-16",
"first_cert_date": "2012-11-26",
"no": "11",
"type": "연구개발유형",
"valid_period": "2025-11-26 ~ 2028-11-25"
}
],
"company_name": "파미셀 주식회사",
"corp_no": "160111-*******",
"financials": {
"2022": {
"capital_stock": 30008482000,
"cost_of_sales": 36362213000,
"current_assets": 62363173000,
"current_liabilities": 28546176000,
"gross_profit": 23819594000,
"net_income": 5968957000,
"net_income_bs": 8261768000,
"non_current_assets": 47284016000,
"non_current_liabilities": 4436098000,
"non_operating_expenses": 6238995000,
"non_operating_income": 3334585000,
"operating_profit": 8873367000,
"revenue": 60181807000,
"sga_expenses": 14946227000,
"total_assets": 109647189000,
"total_equity": 76664915000,
"total_liabilities": 32982274000
},
"2023": {
"capital_stock": 30008481000,
"cost_of_sales": 40735416000,
"current_assets": 43166152000,
"current_liabilities": 7763157000,
"gross_profit": 15491963000,
"net_income": 4732058000,
"net_income_bs": 3577984000,
"non_current_assets": 49352601000,
"non_current_liabilities": 4358650000,
"non_operating_expenses": 2938699000,
"non_operating_income": 6374760000,
"operating_profit": 1295997000,
"revenue": 56227379000,
"sga_expenses": 14195966000,
"total_assets": 92518753000,
"total_equity": 80396946000,
"total_liabilities": 12121807000
},
"2024": {
"capital_stock": 30008482000,
"cost_of_sales": 43521158000,
"current_assets": 48035031000,
"current_liabilities": 7645983000,
"gross_profit": 21330146000,
"net_income": 6263975000,
"net_income_bs": 6331277000,
"non_current_assets": 51229286000,
"non_current_liabilities": 5179164000,
"non_operating_expenses": 1109001000,
"non_operating_income": 2717339000,
"operating_profit": 4655637000,
"revenue": 64851304000,
"sga_expenses": 16674509000,
"total_assets": 99264317000,
"total_equity": 86439170000,
"total_liabilities": 12825147000
}
},
"industry": "그 외 기타 분류 안된 화학제품 제조업",
"investment": [],
"main_products": "줄기세포치료제",
"phone": "02-3496-****",
"years": [
2024,
2023,
2022
]
}Data Quality: 95/10 | Primary Source: DART | Section Coverage: 8/8
| Section | Source: | Status |
|---|---|---|
| Basic Info | DART | Collected |
| Financial Statements | Venture System | Collected |
| Investment Metrics | Venture System | Collected |
| Officers | DART | Collected |
| Employment | Public Data | Collected |
| Certifications | Public Data | Collected |
| Patents | KIPRIS | Collected |
| Procurement | G2B Procurement | Collected |
| API | Collected | Status |
|---|---|---|
| nps | 2026-03-05 | Collected |
| DART Financial | 2026-02-26 | Collected |
| G2B Procurement | 2026-02-25 | Collected |
| Employment Insurance | 2026-02-25 | Collected |
| KIPRIS Patents | 2026-02-25 | Collected |
| HomeTax Business | 2026-02-25 | Collected |
| Cert. Info | 2026-02-25 | Collected |
| Venture System Detail | 2026-02-25 | Collected |